NO330241B1 - Fremgangsmate for a identifisere forbindelser som endrer fosforylering av det humane klokkeproteinet hPERIODE1 (hPER1) - Google Patents
Fremgangsmate for a identifisere forbindelser som endrer fosforylering av det humane klokkeproteinet hPERIODE1 (hPER1) Download PDFInfo
- Publication number
- NO330241B1 NO330241B1 NO20015972A NO20015972A NO330241B1 NO 330241 B1 NO330241 B1 NO 330241B1 NO 20015972 A NO20015972 A NO 20015972A NO 20015972 A NO20015972 A NO 20015972A NO 330241 B1 NO330241 B1 NO 330241B1
- Authority
- NO
- Norway
- Prior art keywords
- cell
- hckie
- protein
- hper1
- phosphorylation
- Prior art date
Links
- 238000006366 phosphorylation reaction Methods 0.000 title claims abstract description 84
- 230000026731 phosphorylation Effects 0.000 title claims abstract description 83
- 150000001875 compounds Chemical class 0.000 title claims abstract description 66
- 238000000034 method Methods 0.000 title claims abstract description 47
- 101000882921 Homo sapiens Circadian locomoter output cycles protein kaput Proteins 0.000 title claims description 4
- 102000051667 human CLOCK Human genes 0.000 title claims description 4
- 230000008859 change Effects 0.000 title description 23
- 230000015556 catabolic process Effects 0.000 claims abstract description 12
- 238000006731 degradation reaction Methods 0.000 claims abstract description 12
- 210000004027 cell Anatomy 0.000 claims description 126
- 108090000623 proteins and genes Proteins 0.000 claims description 111
- 101000579484 Homo sapiens Period circadian protein homolog 1 Proteins 0.000 claims description 110
- 102100028293 Period circadian protein homolog 1 Human genes 0.000 claims description 107
- 102000004169 proteins and genes Human genes 0.000 claims description 102
- 235000018102 proteins Nutrition 0.000 claims description 101
- 238000012216 screening Methods 0.000 claims description 18
- 210000002569 neuron Anatomy 0.000 claims description 11
- 102000005403 Casein Kinases Human genes 0.000 claims description 5
- 108010031425 Casein Kinases Proteins 0.000 claims description 5
- 230000001580 bacterial effect Effects 0.000 claims description 5
- 210000004671 cell-free system Anatomy 0.000 claims description 5
- 210000002950 fibroblast Anatomy 0.000 claims description 5
- 210000003292 kidney cell Anatomy 0.000 claims description 4
- 210000004962 mammalian cell Anatomy 0.000 claims description 4
- 241000238631 Hexapoda Species 0.000 claims description 3
- 210000005253 yeast cell Anatomy 0.000 claims description 3
- 210000001130 astrocyte Anatomy 0.000 claims description 2
- 210000004958 brain cell Anatomy 0.000 claims description 2
- 210000004413 cardiac myocyte Anatomy 0.000 claims description 2
- 210000003887 myelocyte Anatomy 0.000 claims description 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 claims description 2
- 210000004881 tumor cell Anatomy 0.000 claims description 2
- 210000003527 eukaryotic cell Anatomy 0.000 claims 2
- 210000001236 prokaryotic cell Anatomy 0.000 claims 2
- 210000005260 human cell Anatomy 0.000 claims 1
- 210000002751 lymph Anatomy 0.000 claims 1
- 210000004498 neuroglial cell Anatomy 0.000 claims 1
- 238000012360 testing method Methods 0.000 abstract description 52
- 102000007001 Period Circadian Proteins Human genes 0.000 abstract description 26
- 108010047728 Period Circadian Proteins Proteins 0.000 abstract description 26
- 230000027288 circadian rhythm Effects 0.000 abstract description 19
- 241000124008 Mammalia Species 0.000 abstract description 10
- 230000003993 interaction Effects 0.000 abstract description 8
- 101001073216 Homo sapiens Period circadian protein homolog 2 Proteins 0.000 description 64
- 102100035787 Period circadian protein homolog 2 Human genes 0.000 description 60
- 235000001014 amino acid Nutrition 0.000 description 35
- 150000001413 amino acids Chemical class 0.000 description 35
- 101000601274 Homo sapiens Period circadian protein homolog 3 Proteins 0.000 description 28
- 239000013598 vector Substances 0.000 description 27
- 102100037630 Period circadian protein homolog 3 Human genes 0.000 description 25
- 230000000694 effects Effects 0.000 description 25
- OGKYMFFYOWUTKV-UHFFFAOYSA-N N-(2-aminoethyl)-5-chloroisoquinoline-8-sulfonamide Chemical compound C1=NC=C2C(S(=O)(=O)NCCN)=CC=C(Cl)C2=C1 OGKYMFFYOWUTKV-UHFFFAOYSA-N 0.000 description 19
- 102100031065 Choline kinase alpha Human genes 0.000 description 18
- 239000006166 lysate Substances 0.000 description 16
- 108020004999 messenger RNA Proteins 0.000 description 15
- 238000001262 western blot Methods 0.000 description 15
- 238000001890 transfection Methods 0.000 description 14
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 12
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 12
- -1 hydrogen Chemical class 0.000 description 11
- 239000000463 material Substances 0.000 description 11
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 11
- 108700026244 Open Reading Frames Proteins 0.000 description 10
- 239000011324 bead Substances 0.000 description 10
- 230000007423 decrease Effects 0.000 description 10
- 108010049812 Casein Kinase I Proteins 0.000 description 9
- 102000008122 Casein Kinase I Human genes 0.000 description 9
- 108091000080 Phosphotransferase Proteins 0.000 description 9
- 238000007792 addition Methods 0.000 description 9
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 102000020233 phosphotransferase Human genes 0.000 description 9
- 239000000758 substrate Substances 0.000 description 9
- 102100037398 Casein kinase I isoform epsilon Human genes 0.000 description 8
- 101710176553 Casein kinase I isoform epsilon Proteins 0.000 description 8
- 102000011632 Caseins Human genes 0.000 description 8
- 108010076119 Caseins Proteins 0.000 description 8
- 125000000539 amino acid group Chemical group 0.000 description 8
- 125000003277 amino group Chemical group 0.000 description 8
- 239000005018 casein Substances 0.000 description 8
- 235000021240 caseins Nutrition 0.000 description 8
- 230000002060 circadian Effects 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 8
- 101001126582 Homo sapiens Post-GPI attachment to proteins factor 3 Proteins 0.000 description 7
- 229920002684 Sepharose Polymers 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 7
- 210000000221 suprachiasmatic nucleus Anatomy 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 6
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
- 238000001114 immunoprecipitation Methods 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 229960004452 methionine Drugs 0.000 description 6
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 6
- 229910019142 PO4 Inorganic materials 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 229930182817 methionine Natural products 0.000 description 5
- 239000013615 primer Substances 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 230000033764 rhythmic process Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 241000282412 Homo Species 0.000 description 4
- 102000002131 PAS domains Human genes 0.000 description 4
- 108050009469 PAS domains Proteins 0.000 description 4
- 239000012722 SDS sample buffer Substances 0.000 description 4
- 238000000376 autoradiography Methods 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 235000018417 cysteine Nutrition 0.000 description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 102000057681 human PER2 Human genes 0.000 description 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 4
- 230000006951 hyperphosphorylation Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000000021 kinase assay Methods 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 230000003239 periodontal effect Effects 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000010361 transduction Methods 0.000 description 4
- 230000026683 transduction Effects 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 108010052419 NF-KappaB Inhibitor alpha Proteins 0.000 description 3
- 102000018745 NF-KappaB Inhibitor alpha Human genes 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 102000044565 human PER1 Human genes 0.000 description 3
- 102000050276 human PER3 Human genes 0.000 description 3
- 239000012133 immunoprecipitate Substances 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 239000012139 lysis buffer Substances 0.000 description 3
- 230000010355 oscillation Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 238000000163 radioactive labelling Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 3
- 239000011775 sodium fluoride Substances 0.000 description 3
- 235000013024 sodium fluoride Nutrition 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 2
- 102100037211 Aryl hydrocarbon receptor nuclear translocator-like protein 1 Human genes 0.000 description 2
- 102100034476 CCA tRNA nucleotidyltransferase 1, mitochondrial Human genes 0.000 description 2
- 101000831686 Drosophila melanogaster Protein cycle Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 101000740484 Homo sapiens Aryl hydrocarbon receptor nuclear translocator-like protein 1 Proteins 0.000 description 2
- 101000849001 Homo sapiens CCA tRNA nucleotidyltransferase 1, mitochondrial Proteins 0.000 description 2
- 101000640050 Homo sapiens Protein strawberry notch homolog 1 Proteins 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 101150091206 Nfkbia gene Proteins 0.000 description 2
- 241000276498 Pollachius virens Species 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000008632 circadian clock Effects 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000027405 negative regulation of phosphorylation Effects 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 230000001323 posttranslational effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 235000004400 serine Nutrition 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- WAMWSIDTKSNDCU-ZETCQYMHSA-N (2s)-2-azaniumyl-2-cyclohexylacetate Chemical compound OC(=O)[C@@H](N)C1CCCCC1 WAMWSIDTKSNDCU-ZETCQYMHSA-N 0.000 description 1
- XJLSEXAGTJCILF-RXMQYKEDSA-N (R)-nipecotic acid zwitterion Chemical compound OC(=O)[C@@H]1CCCNC1 XJLSEXAGTJCILF-RXMQYKEDSA-N 0.000 description 1
- BWKMGYQJPOAASG-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid Chemical compound C1=CC=C2CNC(C(=O)O)CC2=C1 BWKMGYQJPOAASG-UHFFFAOYSA-N 0.000 description 1
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 1
- AXAVXPMQTGXXJZ-UHFFFAOYSA-N 2-aminoacetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound NCC(O)=O.OCC(N)(CO)CO AXAVXPMQTGXXJZ-UHFFFAOYSA-N 0.000 description 1
- JLLYLQLDYORLBB-UHFFFAOYSA-N 5-bromo-n-methylthiophene-2-sulfonamide Chemical compound CNS(=O)(=O)C1=CC=C(Br)S1 JLLYLQLDYORLBB-UHFFFAOYSA-N 0.000 description 1
- 108700031308 Antennapedia Homeodomain Proteins 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 241000219195 Arabidopsis thaliana Species 0.000 description 1
- 101100113633 Arabidopsis thaliana CKL9 gene Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102000008025 CLOCK Proteins Human genes 0.000 description 1
- 108010075228 CLOCK Proteins Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 108010047048 Casein Kinase Idelta Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 108700013908 Drosophila PER Proteins 0.000 description 1
- 108700029558 Drosophila dco Proteins 0.000 description 1
- 102100030011 Endoribonuclease Human genes 0.000 description 1
- 101710199605 Endoribonuclease Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 101150077699 HRR25 gene Proteins 0.000 description 1
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 108020004485 Nonsense Codon Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 101150074181 PER2 gene Proteins 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 229940122907 Phosphatase inhibitor Drugs 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 101710149951 Protein Tat Proteins 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 description 1
- 101000965899 Simian virus 40 Large T antigen Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000037037 animal physiology Effects 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 230000006557 circadian rhythm pathway Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000032669 eclosion Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 238000010448 genetic screening Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 230000001418 larval effect Effects 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 230000006742 locomotor activity Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000004458 methylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])[H] 0.000 description 1
- MGJXBDMLVWIYOQ-UHFFFAOYSA-N methylazanide Chemical compound [NH-]C MGJXBDMLVWIYOQ-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 238000000329 molecular dynamics simulation Methods 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000037434 nonsense mutation Effects 0.000 description 1
- 230000005937 nuclear translocation Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 125000006187 phenyl benzyl group Chemical group 0.000 description 1
- 125000000612 phthaloyl group Chemical group C(C=1C(C(=O)*)=CC=CC1)(=O)* 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000030716 positive regulation of phosphorylation Effects 0.000 description 1
- XUWVIABDWDTJRZ-UHFFFAOYSA-N propan-2-ylazanide Chemical compound CC(C)[NH-] XUWVIABDWDTJRZ-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 230000009822 protein phosphorylation Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000021907 regulation of circadian rhythm Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 239000007320 rich medium Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000003007 single stranded DNA break Effects 0.000 description 1
- 230000007958 sleep Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000008521 threonine Nutrition 0.000 description 1
- 150000003588 threonines Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 238000001086 yeast two-hybrid system Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Electrophonic Musical Instruments (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32774599A | 1999-06-08 | 1999-06-08 | |
| PCT/US2000/015633 WO2000075669A1 (en) | 1999-06-08 | 2000-06-07 | Screening methods for altering circadian rhythm proteins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20015972D0 NO20015972D0 (no) | 2001-12-06 |
| NO20015972L NO20015972L (no) | 2002-02-05 |
| NO330241B1 true NO330241B1 (no) | 2011-03-14 |
Family
ID=23277866
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20015972A NO330241B1 (no) | 1999-06-08 | 2001-12-06 | Fremgangsmate for a identifisere forbindelser som endrer fosforylering av det humane klokkeproteinet hPERIODE1 (hPER1) |
| NO20100430A NO20100430L (no) | 1999-06-08 | 2010-03-23 | Anvendelse av en forbindelse for fremstilling av et medikament for a endre den cirkadiske rytme hos et pattedyr |
| NO20100431A NO20100431L (no) | 1999-06-08 | 2010-03-23 | Fremgangsmate for a endre degradering av det humane klokkeproteinet hPeriode1 (hPER1) |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20100430A NO20100430L (no) | 1999-06-08 | 2010-03-23 | Anvendelse av en forbindelse for fremstilling av et medikament for a endre den cirkadiske rytme hos et pattedyr |
| NO20100431A NO20100431L (no) | 1999-06-08 | 2010-03-23 | Fremgangsmate for a endre degradering av det humane klokkeproteinet hPeriode1 (hPER1) |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US6555328B1 (xx) |
| EP (1) | EP1183541B1 (xx) |
| JP (1) | JP4583682B2 (xx) |
| KR (1) | KR100722176B1 (xx) |
| AT (1) | ATE322016T1 (xx) |
| AU (1) | AU767800B2 (xx) |
| BR (1) | BR0011437A (xx) |
| CA (1) | CA2375450C (xx) |
| DE (1) | DE60026998T2 (xx) |
| IL (2) | IL146729A0 (xx) |
| MX (1) | MXPA01011417A (xx) |
| NO (3) | NO330241B1 (xx) |
| NZ (1) | NZ514603A (xx) |
| WO (1) | WO2000075669A1 (xx) |
| ZA (1) | ZA200108962B (xx) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6476188B1 (en) | 1998-06-19 | 2002-11-05 | The Rockefeller University | Clock gene and methods of use thereof |
| US6436628B1 (en) | 1998-06-19 | 2002-08-20 | The Rockefeller University | Methods of identifying an agent which modulates period and doubletime protein interaction |
| US6555328B1 (en) * | 1999-06-08 | 2003-04-29 | Aventis Pharmaceuticals Inc. | Screening methods for altering circadian rhythms and for human casein kinase I δ and/or ε phosphorylation of human clock proteins, period 1, -2 and -3 |
| DE60042280D1 (de) * | 1999-11-18 | 2009-07-09 | Mitsubishi Tanabe Pharma Corp | Transgene säugetiere mit einem period 1 promotor, der rhythmische expression verleiht |
| GB0103110D0 (en) * | 2000-08-25 | 2001-03-28 | Aventis Pharma Inc | A membrane penetrating peptide encoded by a nuclear localization sequence from human period 1 |
| EP1358315A4 (en) * | 2001-01-11 | 2005-11-16 | Univ Utah Res Found | IDENTIFYING AN ADVANCED SLEEP PHASE SYNDROME GENE IN PEOPLE |
| AU2003278333A1 (en) * | 2002-10-25 | 2004-05-13 | University Of Surrey | Polymorphism in the per3 gene as a indicator in the diagnosis and treatment of circadian rhythm sleep disorders |
| WO2004050841A2 (en) * | 2002-11-27 | 2004-06-17 | University Of Utah Research Foundation | Casein kinase i epsilon and casein kinase i delta and sleep in humans |
| JO2724B1 (en) * | 2004-08-19 | 2013-09-15 | افينتس فارماسوتيكالز انك | 3-Alternative-5 -6-Amino Alkyl Indole-2-Carboxyl Acid Amide and Related Isotopes as Casein Kinase Inhibitors |
| SI1791537T1 (sl) * | 2004-08-19 | 2010-02-26 | Aventis Pharma Inc | 3-ariltioindol-2-karboksamidni derivati in njihovi analogi kot inhibitorji kazein-kinaze I |
| JO2629B1 (en) * | 2004-08-19 | 2012-06-24 | افينتيس فارما سوتيكالز انك | Branched carboxylic acid amides containing thienobirol, carboxylic acid amides containing pyrolithiazole, and the like as kinase inhibitors casein epsilon |
| JP2009538597A (ja) * | 2006-05-31 | 2009-11-12 | 独立行政法人放射線医学総合研究所 | 光誘導性周期的発現遺伝子及び体内時計システムに影響を与える物質のスクリーニング方法 |
| WO2008066626A2 (en) * | 2006-10-25 | 2008-06-05 | The Rockefeller University | METHODS FOR THE TREATMENT OF Aβ RELATED DISORDERS AND COMPOSITIONS THEREFOR |
| FR2918986B1 (fr) | 2007-07-19 | 2009-09-04 | Sanofi Aventis Sa | Derives de 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]- pyridazine, leur preparation et leur application en therapeutique |
| WO2015054819A1 (en) * | 2013-10-14 | 2015-04-23 | Nanjing University | Method for identifying advanced feeding rhythm syndrome and application thereof |
| KR101600144B1 (ko) * | 2013-12-20 | 2016-03-04 | 서울대학교산학협력단 | 일주기 리듬 수면장애 및 시차 부적응에 대한 예방 또는 치료제 스크리닝 방법 |
| US9944648B2 (en) | 2014-01-09 | 2018-04-17 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2017083835A1 (en) * | 2015-11-13 | 2017-05-18 | The Trustees Of Columbia University In The City Of New York | Inhibition of tor complex 2 increases immunity against bacterial infection |
| WO2023129377A1 (en) * | 2022-01-03 | 2023-07-06 | The Johns Hopkins University | Methods and materials for treating heart attack |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH1157137A (ja) * | 1997-08-28 | 1999-03-02 | Sanyo Bussan Kk | 遊技機用特別図柄表示装置 |
| KR100246893B1 (ko) * | 1997-12-29 | 2000-05-01 | 윤종용 | 전자렌지용 도어 |
| AU3976099A (en) * | 1998-05-07 | 1999-11-23 | President & Fellows Of Harvard College, The | Compositions and methods involving regulation of mammalian circadian rhythms |
| US6555328B1 (en) * | 1999-06-08 | 2003-04-29 | Aventis Pharmaceuticals Inc. | Screening methods for altering circadian rhythms and for human casein kinase I δ and/or ε phosphorylation of human clock proteins, period 1, -2 and -3 |
-
2000
- 2000-06-07 US US09/589,462 patent/US6555328B1/en not_active Expired - Lifetime
- 2000-06-07 NZ NZ514603A patent/NZ514603A/en not_active IP Right Cessation
- 2000-06-07 AU AU54689/00A patent/AU767800B2/en not_active Ceased
- 2000-06-07 KR KR1020017015764A patent/KR100722176B1/ko not_active IP Right Cessation
- 2000-06-07 EP EP00939629A patent/EP1183541B1/en not_active Expired - Lifetime
- 2000-06-07 AT AT00939629T patent/ATE322016T1/de active
- 2000-06-07 DE DE60026998T patent/DE60026998T2/de not_active Expired - Lifetime
- 2000-06-07 BR BR0011437-5A patent/BR0011437A/pt not_active Application Discontinuation
- 2000-06-07 JP JP2001501893A patent/JP4583682B2/ja not_active Expired - Fee Related
- 2000-06-07 MX MXPA01011417A patent/MXPA01011417A/es active IP Right Grant
- 2000-06-07 IL IL14672900A patent/IL146729A0/xx active IP Right Grant
- 2000-06-07 WO PCT/US2000/015633 patent/WO2000075669A1/en active IP Right Grant
- 2000-06-07 CA CA002375450A patent/CA2375450C/en not_active Expired - Fee Related
-
2001
- 2001-10-30 ZA ZA200108962A patent/ZA200108962B/en unknown
- 2001-11-25 IL IL146729A patent/IL146729A/en not_active IP Right Cessation
- 2001-12-06 NO NO20015972A patent/NO330241B1/no not_active IP Right Cessation
-
2010
- 2010-03-23 NO NO20100430A patent/NO20100430L/no not_active Application Discontinuation
- 2010-03-23 NO NO20100431A patent/NO20100431L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA01011417A (es) | 2002-06-04 |
| NO20100430L (no) | 2002-02-05 |
| NZ514603A (en) | 2003-10-31 |
| US6555328B1 (en) | 2003-04-29 |
| ZA200108962B (en) | 2003-01-30 |
| EP1183541B1 (en) | 2006-03-29 |
| BR0011437A (pt) | 2002-03-05 |
| JP2003501074A (ja) | 2003-01-14 |
| AU767800B2 (en) | 2003-11-27 |
| NO20015972L (no) | 2002-02-05 |
| ATE322016T1 (de) | 2006-04-15 |
| CA2375450C (en) | 2009-04-28 |
| AU5468900A (en) | 2000-12-28 |
| DE60026998T2 (de) | 2007-04-05 |
| KR100722176B1 (ko) | 2007-05-29 |
| WO2000075669A1 (en) | 2000-12-14 |
| JP4583682B2 (ja) | 2010-11-17 |
| KR20020033101A (ko) | 2002-05-04 |
| NO20100431L (no) | 2002-02-05 |
| IL146729A0 (en) | 2002-07-25 |
| EP1183541A1 (en) | 2002-03-06 |
| NO20015972D0 (no) | 2001-12-06 |
| IL146729A (en) | 2007-06-17 |
| DE60026998D1 (de) | 2006-05-18 |
| CA2375450A1 (en) | 2000-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO330241B1 (no) | Fremgangsmate for a identifisere forbindelser som endrer fosforylering av det humane klokkeproteinet hPERIODE1 (hPER1) | |
| Chung et al. | PAKa, a putative PAK family member, is required for cytokinesis and the regulation of the cytoskeleton in Dictyostelium discoideum cells during chemotaxis | |
| Livingstone et al. | ATF‐2 contains a phosphorylation‐dependent transcriptional activation domain. | |
| Fiol et al. | A secondary phosphorylation of CREB341 at Ser129 is required for the cAMP-mediated control of gene expression. A role for glycogen synthase kinase-3 in the control of gene expression. | |
| Brandeis et al. | The proteolysis of mitotic cyclins in mammalian cells persists from the end of mitosis until the onset of S phase. | |
| Llorian et al. | SIPP1, a novel pre-mRNA splicing factor and interactor of protein phosphatase-1 | |
| Anderson et al. | Ca 2+/calmodulin-dependent protein kinase IV and calcium signaling | |
| Bisson et al. | EphA4 signaling regulates blastomere adhesion in the Xenopus embryo by recruiting Pak1 to suppress Cdc42 function | |
| Garcia-Gonzalo et al. | Interaction between HERC1 and M2-type pyruvate kinase | |
| US8389207B2 (en) | Methods for identifying candidate fat-mobilizing agents | |
| Boratkó et al. | Elongation factor-1A1 is a novel substrate of the protein phosphatase 1-TIMAP complex | |
| Masson et al. | In vitro phosphorylation studies of a conserved region of the transcription factor ATF1 | |
| Kalmes et al. | Interaction between the protein kinase B-Raf and the α-subunit of the 11S proteasome regulator | |
| Schiller et al. | Induction of lamellipodia by Kalirin does not require its guanine nucleotide exchange factor activity | |
| Fukumoto et al. | The polyanionic C-terminal tail of human Rad17 regulates interaction with the 9–1–1 complex | |
| US20020106690A1 (en) | The g-protein b subunit interaction domain of ste20p/pak family of protein kinases and uses thereof in bioassays | |
| Rutherford et al. | Phosphorylation-independent internalisation and desensitisation of the human sphingosine-1-phosphate receptor S1P3 | |
| Alex | Mechanistic insights into the mitotic checkpoint through biochemical characterisation and in vivo method development | |
| US20050181360A1 (en) | Assay for cell cycle modulators based on the modulation of cyclin d1 degradation in response to ionising radiation | |
| Delpire et al. | Ste20 kinases and cation-chloride cotransporters | |
| McCollami et al. | Pleckstrin and Dbl Homology Regions in the Ras Exchange | |
| CA2286073A1 (en) | Screening for compounds that inhibit phosphorylation of i?b.alpha. | |
| Lee | Mechanism of inhibitory action of nitric oxide on hepatic stellate cell migration and motility | |
| Palazzo | The regulation of microtubule organization by small Rho GTPases and integrin signals | |
| Remy et al. | Regulation of Apoptosis by the Ft1 Protein |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |